Watch the video and download the slides.


Individualising treatment strategies for nmCRPC

GU CONNECT expert, Dr Ray Manneh Kopp discusses treatment strategies for non-metastatic castration-resistant prostate cancer (nmCRPC) and how to individualise them by considering the patient profile, potential risk-benefit, comorbidities, drug-drug interactions and cognitive function.
Watch the video and download the slides.

Individualising treatment strategies for nmCRPC

Hello everyone, I'm Dr Ray Manneh, I'm a GU oncologist at the Society of Oncology and Hematology from del Cesar in Colombia and I'm going to talk about how to individualise treatment strategies for non-metastatic castration-resistant prostate cancer.

We are going to see the slight differences in the drugs that will help us to choose the best treatment for each patient.

Non-metastatic castration-resistant prostate cancer is defined by rising PSA levels with testosterone in castration levels without evidence of metastasis by conventional imaging.

Patient Population Considerations

We know that this patient population is at higher risk of dying from prostate cancer and we have to treat them in order to prolong their life while maintaining their quality of life.

As you know these are elderly patients, they have comorbidities, and we have to maintain their quality of life without increasing their risk factors.

nmCRPC Treatment Strategy

The alternatives we have are apalutamide, enzalutamide and darolutamide. Darolutamide has a distinct structure, and we should know that it has a less penetration of the blood-brain barrier. This could lead in a better safety profile.

We have to choose the best treatment for each patient and the first thing that that we should know is that when we are choosing the treatment strategy, it doesn't matter the age of the patient.

At ASCO this year Dr Fallah showed that the patient with more than 80 years derived the same magnitude of benefit than younger patients. What he also showed was that they had more frequent adverse events, so these adverse events were fatigue, hypertension, falls, cardiovascular events and cognitive impairments.

We have to evaluate at baseline their cardiovascular risk, we have to do lots of awareness in the patient and with their family, we have to take in consideration drug-drug interactions, and we also have to evaluate cognitive dysfunction at baseline and at every visit to avoid this issue.

Take-Home Messages

The take-home messages are that these patients are asymptomatic we have to carefully choose the treatment according to the patient profile.

Doing the risk benefit analysis, we will most of the time choose to start treatments, but we have to evaluate their comorbidities, their cardiovascular risk and their baseline cognitive function not only with the patient but also with their caregivers.

Thank you very much on behalf of GU CONNECT.  You can go to guconnect.cor2ed.com to download the slides.

Scientific director at Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia. Chief of Genitourinary Unit and Clinical Research Unit. Medical Oncologist at Clínica Portoazul, Barranquilla, Colombia. I completed medical school at Universidad del Norte, Barranquilla Colombia.  Medical oncologist from University Hospital 12 de Octubre in Madrid, Genitourinary Fellow in the GU unit at  University Hospital 12 de Octubre. Master in molecular oncology from Centro de estudios biosanitarios, CNIIO, ESO. Founder of Grupo de Oncología Genitourinaria de Colombia.  Member of SEOM, ACHO and LACOG-GU. I focus my practice on patients with prostate, bladder, kidney and testicular cancer. 

Dr Ray Manneh Kopp has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, AstraZeneca, BMS, Dr Reddys, Roche, Janssen, Lilly, MSD, Novartis and Technofarma.

Programme summary
Play the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

podcast Podcast
Oncology 
Prostate cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 1 of a 3-part video podcast series

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resouces
  • clock 30 MIN
  • calendar Nov 2023

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

An interactive patient case video series from breast cancer specialists

Experts
Prof. Valentina Guarneri
Endorsed by
GRASP
  • clock 15 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology
conference-update Conference update
Oncology 
GI highlights from ESMO 2023

An expert panel discussion hosted by COR2ED and eChinaHealth

  • clock 50 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from BeiGene Europe and SystImmune.
conference-update Conference update
Oncology 
RCC Update from ESMO 2023

How will the latest data impact clinical practice?

Experts
Prof. Laurence Albiges
  • download Downloadable
    Resouces
  • clock 4 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Eisai Europe Limited.
conference-update Conference update
Oncology 
Lung cancer highlights from ESMO 2023

An expert panel discussion hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Oct 2023

This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.
conference-update Conference update
Oncology 
Precision Oncology Update From ESMO 2023

How will the latest data impact clinical practice?

Experts
Dr Philipp Ivanyi
  • download Downloadable
    Resouces
  • clock 3 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Bayer.